Login Register Cart 0
Generic placeholder image

Protein & Peptide Letters

Editor-in-Chief

ISSN (Print): 0929-8665
ISSN (Online): 1875-5305

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Long Non-coding RNA UCA1 Regulates SRPK1 Expression Through miR- 99b-3p in Ovarian Cancer

Author(s): Juan Xu, Liu-hong Zheng, Yi-nuo Hong, Cheng Xuan, Shu-ling Yan, Guo-Liang Lv, Zheng-Gang Jiang* and Xian-Feng Ding*

Volume 29, Issue 10, 2022

Published on: 19 September, 2022

Page: [829 - 838] Pages: 10

DOI: 10.2174/0929866529666220704122019

Price: $65

Abstract

Background: Ovarian carcinoma (OC) is one of the most common malignancies of the female reproductive organs, with a low survival rate primarily due to the lack of effective methods for early diagnosis and prognosis.

Objective: In this article, our motivation is to explore the lncRNA-related network mechanisms involved in the pathogenesis of OC.

Methods: Public lncRNAs and mRNA expression datasets for OC were collected from the Gene Expression Omnibus (GEO) database. By integrated bioinformatics analysis, we constructed a UCA1-miRNA-mRNA network. We studied lncRNA-related molecular modulation mechanism in ovarian cancer cells based on MTT assay, dual luciferase reporter gene assays, quantitative realtime PCR, and western blotting.

Results: UCA1 was higher in ovarian tumor tissues and cells than normal tissues and cells. It was demonstrated in this study that knockdown of UCA1 inhibited ovarian cancer cell viability, which a miR-99b-3p inhibitor could reverse in vitro. Further, UCA1 was shown to regulate the expression of SRPK1 by directly binding to miR-99b-3p.

Conclusion: These results suggest that UCA1 functions as an oncogene in ovarian cancer. Inhibition of UCA1/miR-99b-3p/SRPK1 axis may become a novel target for treating ovarian cancer.

Keywords: lncRNA UCA1, miR-99b-3p, ovarian cancer, SRPK1, gynecological malignancy, UTR.

« Previous Next »
Graphical Abstract

[1]
Mi, Y.; Huang, Y.; Deng, J. The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles. Oncol. Lett., 2018, 15(5), 6611-6621.
[http://dx.doi.org/10.3892/ol.2018.8140] [PMID: 29725407]
[2]
Mahmoud, E.H.; Fawzy, A.; A., Elshimy R.A. A, E.R. Serum microRNA-21 negatively relates to expression of programmed cell Death-4 in patients with epithelial ovarian cancer. Asian Pac. J. Cancer Prev., 2018, 19(1), 33-38.
[http://dx.doi.org/10.22034/APJCP.2018.19.1.33] [PMID: 29373877]
[3]
Mirahmadi, Y.; Nabavi, R.; Taheri, F.; Samadian, M.M.; Ghale-Noie, Z.N.; Farjami, M.; Samadi-Khouzani, A.; Yousefi, M.; Azhdari, S.; Salmaninejad, A.; Sahebkar, A. microRNAs as biomarkers for early diagnosis, prognosis, and therapeutic targeting of ovarian cancer. J. Oncol., 2021, 2021, 3408937.
[http://dx.doi.org/10.1155/2021/3408937] [PMID: 34721577]
[4]
Yao, S.; Li, L.; Su, X.T.; Wang, K.; Lu, Z.J.; Yuan, C.Z.; Feng, J.B.; Yan, S.; Kong, B.H.; Song, K. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: In vitro and in vivo. J. Exp. Clin. Cancer Res., 2018, 37(1), 29.
[http://dx.doi.org/10.1186/s13046-018-0700-z] [PMID: 29478415]
[5]
Dahiya, N.; Sherman-Baust, C.A.; Wang, T.L.; Davidson, B.; Shih, IeM.; Zhang, Y.; Wood, W., III; Becker, K.G.; Morin, P.J. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One, 2008, 3(6), e2436.
[http://dx.doi.org/10.1371/journal.pone.0002436] [PMID: 18560586]
[6]
Fu, L.L.; Li, C.J.; Xu, Y.; Li, L.Y.; Zhou, X.; Li, D.D.; Chen, S.X.; Wang, F.G.; Zhang, X.Y.; Zheng, L.W. Role of lncRNAs as novel biomarkers and therapeutic targets in ovarian cancer. Crit. Rev. Eukaryot. Gene Expr., 2017, 27(2), 183-195.
[http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2017019244] [PMID: 28845767]
[7]
Zheng, L.; Zhang, Y.; Fu, Y.; Gong, H.; Guo, J.; Wu, K.; Jia, Q.; Ding, X. Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer. Biosci. Rep., 2019, 39(2), BSR20181284.
[http://dx.doi.org/10.1042/BSR20181284] [PMID: 30683807]
[8]
Xu, J.; Wu, K.J.; Jia, Q.J.; Ding, X.F. Roles of miRNA and lncRNA in triple-negative breast cancer. J. Zhejiang Univ. Sci. B, 2020, 21(9), 673-689.
[http://dx.doi.org/10.1631/jzus.B1900709] [PMID: 32893525]
[9]
Wang, J.Y.; Lu, A.Q.; Chen, L.J. LncRNAs in ovarian cancer. Clin. Chim. Acta, 2019, 490, 17-27.
[http://dx.doi.org/10.1016/j.cca.2018.12.013] [PMID: 30553863]
[10]
Yao, F.; Wang, Q.; Wu, Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag. Res., 2019, 11(11), 7685-7696.
[http://dx.doi.org/10.2147/CMAR.S200436] [PMID: 31616184]
[11]
He, A.; Hu, R.; Chen, Z.; Liao, X.; Li, J.; Wang, D.; Lv, Z.; Liu, Y.; Wang, F.; Mei, H. Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a meta-analysis. Oncotarget, 2017, 8(1), 1937-1943.
[http://dx.doi.org/10.18632/oncotarget.12463] [PMID: 27713161]
[12]
Yan, Q.; Tian, Y.; Hao, F.R. Downregulation of lncRNA UCA1 inhibits proliferation and invasion of cervical cancer cells through miR-206 expression; Oncol Res Featur Preclin Clin Cancer Ther, 2018. Epub ahead of print
[http://dx.doi.org/10.3727/096504018X15185714083446] [PMID: 29523226]
[13]
Gu, L.; Lu, L.S.; Zhou, D.L.; Liu, Z.C. UCA1 promotes cell proliferation and invasion of gastric cancer by targeting CREB1 sponging to miR-590-3p. Cancer Med., 2018, 7(4), 1253-1263.
[http://dx.doi.org/10.1002/cam4.1310] [PMID: 29516678]
[14]
Wang, H.M.; Lu, J.H.; Chen, W.Y.; Gu, A.Q. Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma. Int. J. Clin. Exp. Med., 2015, 8(7), 11824-11830.
[PMID: 26380024]
[15]
Hong, H.H.; Hou, L.K.; Pan, X.; Wu, C.Y.; Huang, H.; Li, B.; Nie, W. Long non-coding RNA UCA1 is a predictive biomarker of cancer. Oncotarget, 2016, 7(28), 44442-44447.
[http://dx.doi.org/10.18632/oncotarget.10142]
[16]
Patel, M.; Sachidanandan, M.; Adnan, M. Serine arginine protein kinase 1 (SRPK1): A moonlighting protein with theranostic ability in cancer prevention. Mol. Biol. Rep., 2019, 46(1), 1487-1497.
[http://dx.doi.org/10.1007/s11033-018-4545-5] [PMID: 30535769]
[17]
Bullock, N.; Oltean, S. The many faces of SRPK1. J. Pathol., 2017, 241(4), 437-440.
[http://dx.doi.org/10.1002/path.4846] [PMID: 27859253]
[18]
Odunsi, K.; Mhawech-Fauceglia, P.; Andrews, C.; Beck, A.; Amuwo, O.; Lele, S.; Black, J.D.; Huang, R.Y. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PLoS One, 2012, 7(12), e51030.
[http://dx.doi.org/10.1371/journal.pone.0051030] [PMID: 23236423]
[19]
Yue, H.; Li, W.; Chen, R.; Wang, J.; Lu, X.; Li, J. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer. Gynecol. Oncol., 2021, 160(2), 530-538.
[http://dx.doi.org/10.1016/j.ygyno.2020.11.026] [PMID: 33317907]
[20]
Wang, J.; Ye, C.; Liu, J.; Hu, Y. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem. Biophys. Res. Commun., 2018, 501(4), 1034-1040.
[http://dx.doi.org/10.1016/j.bbrc.2018.05.104] [PMID: 29777711]
[21]
Yang, Y.; Jiang, Y.; Wan, Y.; Zhang, L.; Qiu, J.; Zhou, S.; Cheng, W. UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis. Tumour Biol., 2016, 37(8), 10633-10641.
[http://dx.doi.org/10.1007/s13277-016-4917-1] [PMID: 26867765]
[22]
Zhang, L.; Cao, X.; Zhang, L.; Zhang, X.; Sheng, H.; Tao, K. UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy. Cancer Chemother. Pharmacol., 2016, 77(3), 629-634.
[http://dx.doi.org/10.1007/s00280-016-2963-4] [PMID: 26851957]
[23]
Chen, X.; Gao, J.; Yu, Y.; Zhao, Z.; Pan, Y. RETRACTED: Long non-coding RNA UCA1 targets miR-185-5p and regulates cell mobility by affecting epithelial-mesenchymal transition in melanoma via Wnt/β-catenin signaling pathway. Gene, 2018, 676, 298-305.
[http://dx.doi.org/10.1016/j.gene.2018.08.065] [PMID: 30144501]
[24]
Gong, P.; Qiao, F.; Wu, H.; Cui, H.; Li, Y.; Zheng, Y.; Zhou, M.; Fan, H. LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastric cancer. Cell Death Dis., 2018, 9(12), 1158.
[http://dx.doi.org/10.1038/s41419-018-1170-0] [PMID: 30464170]
[25]
Yu, R.; Zhang, Y.; Lu, Z.; Li, J.; Shi, P.; Li, J. Long-chain non-coding RNA UCA1 inhibits renal tubular epithelial cell apoptosis by targeting microRNA-206 in diabetic nephropathy. Arch. Physiol. Biochem., 2022, 128(1), 231-239.
[http://dx.doi.org/10.1080/13813455.2019.1673431] [PMID: 31608712]
[26]
Yao, X.; Zhang, H.; Liu, Y.; Liu, X.; Wang, X.; Sun, X.; Cheng, Y. miR-99b-3p promotes hepatocellular carcinoma metastasis and proliferation by targeting protocadherin 19. Gene, 2019, 698, 141-149.
[http://dx.doi.org/10.1016/j.gene.2019.02.071] [PMID: 30849536]
[27]
He, K.; Tong, D.; Zhang, S.; Cai, D.; Wang, L.; Yang, Y.; Gao, L.; Chang, S.; Guo, B.; Song, T.; Li, A.; Huang, C. miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3β in oral squamous cell carcinoma Tca-8113 cells. Int. J. Oncol., 2015, 47(4), 1528-1536.
[http://dx.doi.org/10.3892/ijo.2015.3135] [PMID: 26315788]
[28]
Li, Y.; Yu, S.; Wang, X.; Ye, X.; He, B.; Quan, M.; Gao, Y. SRPK1 facilitates tumor cell growth via modulating the small nucleolar RNA expression in gastric cancer. J. Cell. Physiol., 2019, 234(8), 13582-13591.
[http://dx.doi.org/10.1002/jcp.28036] [PMID: 30633341]
[29]
Zhou, B.; Li, Y.; Deng, Q.; Wang, H.; Wang, Y.; Cai, B.; Han, Z.G. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Mol. Cell. Biochem., 2013, 379(1-2), 191-199.
[http://dx.doi.org/10.1007/s11010-013-1641-7] [PMID: 23644876]
[30]
Zhang, Y.; Xu, Y.; Feng, L.; Li, F.; Sun, Z.; Wu, T.; Shi, X.; Li, J.; Li, X. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget, 2016, 7(39), 64148-64167.
[http://dx.doi.org/10.18632/oncotarget.11637] [PMID: 27580177]
[31]
Jiao, C.; Song, Z.; Chen, J.; Zhong, J.; Cai, W.; Tian, S.; Chen, S.; Yi, Y.; Xiao, Y. lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. Oncol. Rep., 2016, 36(5), 2960-2966.
[http://dx.doi.org/10.3892/or.2016.5121] [PMID: 27667646]
[32]
Wang, W.; Hu, W.; Wang, Y.; An, Y.; Song, L.; Shang, P.; Yue, Z. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. Mol. Cancer, 2020, 19(1), 18.
[http://dx.doi.org/10.1186/s12943-020-1132-x] [PMID: 31996265]
[33]
Li, Y.; Zeng, Q.; Qiu, J.; Pang, T.; Xian, J.; Zhang, X. Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206. Cancer Cell Int., 2019, 19(1), 275.
[http://dx.doi.org/10.1186/s12935-019-0958-z] [PMID: 31695578]

Rights & Permissions Print Cite
Article Metrics
7
© 2024 Bentham Science Publishers | Privacy Policy